Detalhe da pesquisa
1.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
2.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
3.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
4.
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Blood Adv
; 6(23): 5969-5979, 2022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149968
5.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Blood Adv
; 6(7): 2219-2229, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933333
6.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Blood Adv
; 6(7): 2207-2218, 2022 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34972214
7.
Critical review of oncology clinical trial design under non-proportional hazards.
Crit Rev Oncol Hematol
; 162: 103350, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989767